When Does Qulipta's Patent Protection End?
Qulipta (atogepant), a medication for the preventive treatment of migraine, is currently protected by several patents. The expiration dates for these patents vary, with some crucial ones for the active ingredient and its use extending into the mid-2030s. For instance, patents related to the composition of matter for atogepant are generally set to expire around 2033 and 2034 [1].
What Happens When Qulipta Patents Expire?
Upon the expiration of relevant patents, the market for Qulipta is expected to open to generic competition. This typically leads to a significant decrease in the drug's price as multiple manufacturers can produce and sell their versions of atogepant [2].
Can Biosimilars Be Developed for Qulipta?
Qulipta is a small molecule drug, not a biologic. Therefore, biosimilars, which are highly similar versions of biologic medicines, are not applicable. Instead, the development of generic versions, which are chemically identical to the original drug, is the relevant pathway for post-patent competition [3].
How Does Qulipta Compare to Other Migraine Preventives?
Qulipta is part of a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists. It is administered orally and targets CGRP, a molecule implicated in migraine pathophysiology [4]. Other CGRP-targeting drugs include those administered via injection or infusion, such as Aimovig, Ajovy, and Emgality, which target either the CGRP ligand or its receptor [5]. Qulipta's oral formulation differentiates it from these injectable/infusible options.
Who Manufactures Qulipta?
Qulipta is manufactured and marketed by AbbVie [1].
What Are the Potential Risks and Side Effects of Qulipta?
Common side effects reported with Qulipta include upper respiratory infection, nausea, and fatigue [4]. More serious side effects, although rare, can occur. Patients should consult their healthcare provider for a full understanding of potential risks.
Where Can I Find More Detailed Patent Information for Qulipta?
Detailed information regarding Qulipta's patent landscape, including specific patent numbers and expiration dates, can be found on patent tracking websites. DrugPatentWatch.com provides comprehensive data on drug patents and their timelines [1].
What is the Current Status of Qulipta's Market Exclusivity?
Qulipta benefits from market exclusivity granted by its patent portfolio. The duration of this exclusivity is tied to the expiration dates of its key patents, with significant protections extending through the mid-2030s [1].
---
Sources:
1. DrugPatentWatch.com
2. U.S. Food & Drug Administration (FDA)
3. U.S. Food & Drug Administration (FDA) - Generic Drugs
4. Qulipta (atogepant) prescribing information
5. U.S. National Library of Medicine - DailyMed